Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram

Gong Zhang1,2†, Yufeng Wang1,3†, Bryan C. Fuchs3, Wei Guo4, David L. Drum1, Derek J. Erstad1, Baomin Shi1, Albert B. DeLeo1, Hui Zheng4, Lei Cai1, Liyuan Zhang1, Kenneth K. Tanabe1 and Xinhui Wang1*

1 Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, 2 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China, 3 Department of General Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China, 4 Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

Background: Sorafenib, a kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC) but provides only a limited survival benefit. Disulfiram (DSF), a drug for treating alcoholism and a chelator of copper (Cu), forms a complex with Cu (DSF/Cu). DSF/Cu is a potent inducer of autophagic apoptosis of cancer stem cells, which can demonstrate drug resistance. Thus, we hypothesized that DSF/Cu could increase the sensitivity of HCC cells to sorafenib by targeting hepatic cancer stem cells.

Methods: The synergistic effect of DSF/Cu and sorafenib on human HCC cell lines was assessed by cell viability MTT assay. Changes in stemness gene expression in HCC cells were investigated by assessing the presence of hepatic cancer stem cells (HCSCs) (defined as ALDH+ cells) using flow cytometry, sphere formation ability as an index of in vitro tumorigenicity, and expression of stemness gene-encoded proteins by western blot. Autophagic apoptosis and the ERK signaling pathway were also assessed by western blot. Most importantly, the in vivo anti-tumor efficacy of DSF/Cu and sorafenib was tested using orthotopic HCC xenografts in mice.

Results: Compared with sorafenib alone, DSF/Cu + sorafenib synergistically inhibited proliferation of all HCC cell lines, decreased the stemness of HCC cells, and increased the autophagy and apoptosis of HCC cells. The mechanism by which DSF/Cu mediated these phenomena with sorafenib was sustained activation of the ERK pathway. The combination of DSF/Cu (formed with endogenous Cu2+) and sorafenib was significantly more effective than sorafenib alone in inhibiting the growth of orthotopic HCC xenografts in mice. This in vivo anti-tumor efficacy was associated with decreased stemness in treated HCC tumors.
INTRODUCTION

Primary liver cancer is the seventh most common malignancy and the fourth leading cause of cancer death worldwide with high rates of incidence (4.7%) and mortality (8.2%) (1, 2). Up to 75-85% of primary liver cancers are hepatocellular carcinoma (HCC) (1). Surgical interventions, including partial hepatectomy, liver transplantation, transarterial chemoembolization, and ablation, are effective in patients with early-stage HCC (3). However, most patients with HCC are diagnosed in the advanced stage, past the optimal time for surgical treatment (4). Therefore, systemic pharmacotherapy and radiotherapy play an important role in patients with advanced HCC, although they do not markedly improve the overall survival rate.

No effective drugs for treating advanced HCC were available until 2007, when sorafenib, a multi-kinase inhibitor, was approved for use, opening a new era in the treatment of advanced HCC. Sorafenib exerts its anti-tumor ability by blocking the RAF/MEK/ERK pathway, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR) (5). Sorafenib prolongs median survival time by 2-3 months and improves the quality of life of patients with advanced HCC (6, 7). However, few HCC patients respond to sorafenib and rapidly become treatment-resistant, resulting in disease progression (8).

In recent years, considerable evidence indicates that hepatic cancer stem cells (HCSCs), the subpopulation of HCC cells considered responsible for HCC initiation, metastasis, and recurrence, are highly resistant to therapy (9, 10). HCSCs possess the characteristics of self-renewal (11), stemness gene expression, and elevated expression of aldehyde dehydrogenase (ALDH+), distinguishing them from bulk tumor cells that are essentially ALDH-. HCSCs (12, 13) also express an array of cell surface markers including CD133, CD90, CD24, EpCAM, CD44, OV6, and CD13 (14). ALDH+ HCC cells contribute to chemoresistance and are associated with a higher rate of metastasis than ALDH- HCC cells (13). As acquired resistance to sorafenib in HCC patients is closely correlated with HCSCs (10, 15, 16), the use of therapies that target HCSCs in combination with sorafenib could improve the efficacy of sorafenib treatment for advanced HCC.

Disulfiram (DSF), a drug used for treating alcoholism since 1951, is an ALDH inhibitor. DSF binds with copper ions (Cu2+) to form DSF/Cu complexes that have anti-tumor efficacy (17). We previously found that pancreatic cancer stem cells (CSCs) and non-stem cells (non-CSCs) are effectively targeted by incorporating DSF/Cu into standard chemoradiation regimens (18). Here, we investigated whether treatment with DSF/Cu increases the sensitivity of HCC cells, in particular HCSCs, to sorafenib in both in vitro and in vivo preclinical experiments.

Conclusions: DSF/Cu and sorafenib can synergistically and effectively treat HCC by targeting HCSCs in vitro and in vivo. Our data provide a foundation for clinical translation.

Keywords: sorafenib, disulfiram, copper, hepatic cancer stem cells, ERK pathway

MATERIALS AND METHODS

Cell Culture

The human HCC cell lines HepG2, Hep3B, SNU387, and SNU423 were obtained from ATCC. HepG2 and Hep3B cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Mediatech, Inc.) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals). SNU387 and SNU423 cell lines were cultured in RPMI 1640 medium (Corning) with 10% FBS. All cell lines were cultured at 37°C in a humidified atmosphere of 5% CO₂.

Chemical Reagents, Antibodies, and Monoclonal Antibodies

Tetraethylthiuram disulfide (disulfiram, DSF), copper (II) D-gluconate(C₄H₈O₄CuO₄) or Copper (II) chloride (CuCl₂), and MEK inhibitor U0126 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sorafenib was obtained from Bayer Corporation ( Whippany, NJ, USA). DSF, sorafenib, and U0126 were reconstituted in DMSO for all in vitro experiments. DSF was reconstituted in olive oil for in vivo experiments. Copper was reconstituted in distilled water for all experiments. ALDH+ cells were determined by ALDH activity measured by ALDEFLUOR® reagent (Stem Cell Technologies, Cambridge, MA, USA).

Antibodies (Ab) and monoclonal Ab (mAb) and their dilutions used for western blotting were specific rabbit mAbs for human ERK1/2 (#4695, 1:1000), human MEK1/2 (#9126, 1:1000), human phosphorylated ERK1/2 (#9101, 1:1000), human phosphorylated MEK1/2 (#9154, 1:1000), human HER2/ERBB2 (#2165, 1:1000), human c-Myc (#9402, 1:1000), LC3A/B (#4108, 1:1000), cleaved PARP (#5625, 1:1000), human β-actin (#4970, 1:2000), specific rabbit mAbs, and goat anti-rabbit IgG HRP-conjugated antibody (#7074, 1:2000), purchased from Cell Signaling Technology (Danvers, MA, USA). Human SOX9-
specific rabbit Ab (ab26414, 1 μg/mL) was purchased from Abcam (Cambridge, MA, USA). All ab were diluted in Tris-buffered saline with 0.1% Tween® 20 (TBST) containing 5% non-fat dry milk plus 2% bovine serum albumin (BSA). All dilutions were prepared immediately before use.

**Animals**

Male NSG mice at 6 weeks of age were obtained from the Massachusetts General Hospital COX7 animal facility. The Institutional Animal Care and Use Committee approved all animal experiments.

**MTT Assay and Synergy Analysis**

HCC cells were plated in 96-well plates at a density of 5000 cells/well in 100 μL appropriate complete medium and incubated overnight. Cells were then treated with the indicated concentrations of drugs for 48 h before determining cell viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma). The synergistic effect of drug combinations was evaluated using the Chou-Talalay method with CompuSyn software (www.compu.syn.com) to calculate combination index (CI) values. CI values of <1, = 1, and >1 indicated synergistic, additive, and antagonistic effects, respectively (24).

**Flow Cytometry**

Cells were seeded in 6-well plates at a density of 2×10^5 cells/well in 2 mL appropriate complete medium and incubated overnight. Cells were then treated with DMSO, DSF/Cu, sorafenib, or DSF/Cu + sorafenib for 12 h, and IC_{50} values (Table 1) of DSF/Cu and sorafenib for each cell line were used for experiments. For the detection of ALDH^+ activity in each cell line, flow cytometry was performed as previously described (18).

**Sphere Formation Assay**

Cells were plated in 24-well plates at a density of 1000 cells/well in 0.5 mL appropriate complete medium followed immediately by treatment with DMSO, DSF, Cu, DSF/Cu, sorafenib, or DSF/Cu + sorafenib for an additional 24 h. IC_{50} values (Table 1) of DSF and sorafenib in each cell line were used for experiments. Sphere formation procedures were performed as previously described (18). For secondary/tertiary sphere formation experiments, primary/secondary spheres were dissociated by tumor/tissue dissociation reagent (BD Biosciences, San Jose, CA, USA) into single cells followed by the same sphere formation procedure. Sphere formation was performed using cells from a single cell suspension collected from HCC cell lines or disaggregated (with collagenase IV, 1 mg/mL in PBS) mouse tumors.

**Statistical Analysis**

For both in vivo and in vitro data, the differences among three or more groups were determined using one-way ANOVA followed by Tukey’s method to adjust for multiple comparisons. Additional two-way ANOVA was adopted as specified. All data are expressed as mean ± standard deviation (SD) unless
specified otherwise. Data were analyzed and graphs were plotted using GraphPad Prism 8 software. Results were obtained from two or three independent experiments. Differences between groups were considered significant when \( p<0.05 \).

**RESULTS**

DSF/Cu and Sorafenib Synergistically Inhibit the Growth of HCC Cells *In Vitro*

Four HCC cell lines—HepG2, Hep3B, SNU387, and SNU423—were used to evaluate the sensitivity of HCC cells to DSF/Cu and/or sorafenib. Cells were treated with a gradient of DSF/Cu concentrations or sorafenib alone for 48 h followed by determination of cell growth inhibition using MTT assay. A fixed dose of 1 \( \mu M \) Cu\(^{2+} \) was used with DSF in these experiments based on our previous experience and related publications (26, 27). DSF/Cu or sorafenib alone suppressed the growth of all four HCC cell lines in a dose-dependent manner (Figures 1A, B). The IC\(_{50}\) values of DSF/Cu and sorafenib alone for the four HCC cell lines are presented in Table 1.

To determine whether DSF/Cu and sorafenib could act synergistically to inhibit the growth of HCC cells, each HCC cell line was treated with DSF/Cu at a fixed concentration that was lower than the IC\(_{50}\) DSF/Cu value for that cell line and various concentrations of sorafenib for 48 h. Combining DSF/Cu with sorafenib significantly increased the inhibition of cell growth compared with sorafenib alone (Figure 1C). Fraction affected values, namely, the fraction of cells inhibited by drugs, were obtained for each HCC cell line. The CI value was calculated from the fraction affected value of each drug combination. At combinations below IC\(_{50}\) values, DSF/Cu showed synergistic interactions (CI<1) with sorafenib at indicated doses in inhibiting the growth of all HCC cell lines (Figure 1D).

HCSCs Are Sensitive to DSF/Cu and Sorafenib

ALDH\(^{+}\) HCSCs in all four HCC cell lines were identified by flow cytometry (Figures 2A–D). DSF/Cu treatment reduced the percentage of ALDH\(^{+}\) cells in all cell lines (Figures 2A–D). In the Hep3B cell line, the percentage of ALDH\(^{+}\) cells increased after sorafenib treatment (\( p=0.0003 \)) (Figure 2B). However, sorafenib had little impact on the percentage of ALDH\(^{+}\) cells in HepG2 and SNU423 cell lines (\( p=0.2558 \) and 0.2324, respectively) (Figures 2A–D). Notably, DSF/Cu + sorafenib was significantly more effective in reducing ALDH\(^{+}\) cells in all four HCC cell lines compared with either drug alone (Figures 2A–D).

A critical characteristic of CSCs is their ability to self-renew, which was assessed using sphere formation assay. As monotherapy, DSF/Cu was more effective than sorafenib in preventing the formation of spheres in HepG2 (\( p<0.001 \), Hep3B (\( p=0.0345 \)), SNU387 (\( p=0.0011 \)), and SNU423 (\( p<0.001 \)) cells (Figures 2E, F). Notably, DSF/Cu + sorafenib resulted in significantly less sphere formation than any single treatment alone (\( p<0.001 \)) except for DSF/Cu alone (\( p>0.05 \)) (Figures 2E, F). By comparing sphere numbers of DSF/Cu vs. DSF treated cells in all 4 cell lines, it is clear that the effect of DSF on targeting HCSCs is Cu-dependent (Figures 2E, F). To determine whether DSF/Cu and sorafenib effects were interrelated, we statistically assessed the interaction effect between DSF/Cu and sorafenib using two-way ANOVA and found that their interaction effect was significant (\( p<0.0001 \) in all four cell lines).
DSF/Cu and Sorafenib Decrease Stemness Gene Expression in HCC Cells

To examine the effect of DSF/Cu and sorafenib on stemness gene expression in HCC cells, the four HCC cell lines were treated with different doses and combinations of drugs and monitored for their expression of stemness genes at the protein level by western blot analysis. Sorafenib decreased HER2 and SOX9 expression but had little impact on c-Myc expression in all cell lines (Figures 3A–D). However, DSF/Cu alone or in combination with sorafenib decreased the expression of all three stemness genes to low or non-detectable levels (Figures 3A–D). These results indicate that DSF/Cu +
Sorafenib could effectively decrease the stemness of HCC cells in vitro, consistent with our previous studies in breast and pancreatic cancer cells (18, 27, 28).

**DSF/Cu and Sorafenib Induce Autophagy and Apoptosis of HCC Cells**

Previously, we demonstrated that DSF/Cu induces autophagic apoptosis in breast cancer and pancreatic ductal adenocarcinoma cell lines (25). The conversion of the cytosolic form of the microtubule-associated protein 1A/1B light chain 3B (LC3-I) to lipid-bound LC3-II is a marker of autophagy, whereas cleavage of poly (ADP-ribose) polymerase (PARP) by caspase-3 is a commonly used marker of apoptosis. To determine whether DSF/Cu + sorafenib could induce autophagy and apoptosis, cell lines were cultured in the presence or absence of DSF/Cu or sorafenib for 12 h followed by western blot analysis to determine LC3-II/LC3-I ratios, which reflect the amount of autophagy, and cleaved PARP levels. Whereas DSF/Cu-induced autophagy and apoptosis in all four cell lines, lower to non-detectable levels of LC3-II/LC3-I conversion and cleaved PARP were detected following treatment with sorafenib alone (Figures 4A–D). As expected, DSF/Cu + sorafenib enhanced the induction of autophagy and apoptosis in all four HCC cell lines in a dose-dependent manner as indicated by LC3-II/LC3-I ratios and cleaved PARP levels (Figures 4A–D). However, the results of autophagy and apoptosis must be interpreted with caution, as an in-depth study on cell death induced by DSF/Cu + sorafenib should be carried out with additional markers and methods (29).

The efficacy of sorafenib against advanced HCC is attributed to its direct inhibitory effects on the growth of HCC cells via the Raf/MEK/ERK signaling pathway and its indirect suppressive effects on HCC angiogenesis via inhibition of receptor tyrosine kinases, including VEGFR and PDGFR (5, 23). Given that DSF/Cu + sorafenib had a more potent anti-tumor effect than sorafenib alone, one hypothesis is that DSF/Cu functions synergistically with sorafenib by also inhibiting the MEK/ERK signaling pathway. To investigate the underlying mechanism involved in this process, the expression of MER/ERK pathway-related proteins in DSF/Cu-treated HCC cell lines was analyzed by western blot. Surprisingly, increased protein levels of...
phosphorylated ERK (p-ERK) and phosphorylated MEK (p-MEK) were detected in all four HCC cell lines in a dose- and time-dependent manner following DSF/Cu treatment (Figures 5A–D). However, a high dose (0.6 μM/1 μM) or a long period (24 h) of DSF/Cu treatment decreased expression of p-ERK and p-MEK in Hep3B (Figure 5B) and SNU387 (Figure 5C) cell lines. Moreover, high expression of MEK/ERK pathway-associated genes was generally associated with low protein expression of stemness, increased autophagy and apoptosis (Figures 5A–D) (Supplementary Figures 1A–G). These findings indicate that the autophagy, apoptosis and stemness of HCC cells were determined by sustained MEK/ERK activation induced by DSF/Cu.

To further confirm this mechanism, HCC cell lines were treated with U0126, a highly selective inhibitor of MEK1/2 and ERK activation, which decreased p-ERK levels (Figures 5E–H). However, U0126 increased p-MEK levels, possibly due to a negative feedback mechanism (30). In addition, U0126 induced apoptosis in HepG2 and SNU387 cell lines and autophagy in SNU387 and SNU423 cell lines (Figures 5E–H). Considering the
expression of stemness genes, U0126 inhibition of ERK activation resulted in mixed responses in HCC cell lines, with increased HER2 expression and decreased SOX9 and c-Myc expression (Figures 5E–H). To investigate the function of DSF/Cu in the MEK/ERK signaling pathway in HCC cells, cells were exposed to DSF/Cu (0.4 μM/1 μM) and different doses of U0126 (1, 5, 10, or 20 μM). The inhibitor partially blocked DSF/Cu-induced conversion of LC3-I to LC3-II and PARP cleavage all four HCC cell lines. However, the effect of U0126 on DSF/Cu-induced downregulation of stemness gene encoded protein expression was not clearly noted (Figures 5E–H).

The DSF With Endogenous Cu^2+ and Sorafenib Is Significantly More Effective Than Sorafenib Alone in Inhibiting the Growth of Orthotopic HCC Xenografts in Mice

To assess whether these in vitro findings could be extended to a preclinical animal tumor model, HepG2 cells were directly

![Figure 6](https://example.com/fig6.png)

**FIGURE 6** | DSF with endogenous Cu^2+ and sorafenib inhibits the growth of orthotopic HCC xenografts in mice more effectively than sorafenib alone. Human HepG2 cells were injected directly into the liver of NSG mice (left) and the resulting orthotopic liver tumor formation (right). (A) Mice were grouped and all the treatments were initiated (on day 4). At the time of sacrifice (on day 24), tumors were resected and measured (B). The sphere formation of cells isolated from the cells collected from xenograft tumors of each mouse group was assessed. Spheres were quantified by counting sphere numbers/well on day 14 (C, D). To monitor toxicity, mouse body weight was measured every 3 days (E). Data are shown as mean ± SD. "p<0.05, ""p<0.01, """"p<0.0001.
injected into the liver of immunodeficient NSG mice to establish orthotopic HCC xenografts (Figure 6A).

Mice treated with sorafenib + DSF had smaller tumors at day 24 than untreated (1.4 ± 0.78 mm vs. 52.9 ± 9.09 mm, p<0.0001) or sorafenib-treated (1.4 ± 0.78 mm vs. 18.55 ± 3.58 mm, p=0.0017) mice. Tumor size was similar between sorafenib + DSF and sorafenib + DSF/Cu groups, but there was a tendency toward reduced tumor volume in the sorafenib + DSF group compared with the sorafenib + DSF/Cu group (1.4 ± 0.78 mm vs. 9.56 ± 6.84 mm) (Figure 6B). Exogenous Cu²⁺ is not necessary for the efficacy of DSF in in vivo experiments due to the existence of endogenous Cu²⁺ in HCC (31) and other types of tumors (27). Sorafenib + DSF exerted a larger anti-tumor effect on third-generation HCSCs, as evidenced by sphere formation compared with no treatment, sorafenib alone, or sorafenib + DSF/Cu (1.50 ± 1.05 vs. 36.67 ± 2.73, 9.83 ± 1.72, and 3.50 ± 1.05; p<0.0001, p<0.0001, and p=0.24, respectively) (Figures 6C, D). This finding suggests that sorafenib monotherapy only partially eliminates HCSCs, whereas sorafenib + DSF eliminates nearly all HCSCs. The interaction effect between DSF and sorafenib indicated a significant difference in terms of tumor volume and third generation of sphere numbers (p<0.0001).

As a preliminary gauge of the potential drug-induced toxicity of combined treatment, mouse body weight was measured every 3 days. The two-way ANOVA followed by the Tukey’s multiplicity comparison were used to determine the interaction between time and treatments (DSF), the results showed significant difference (p<0.0001). Notably, sorafenib alone and sorafenib + DSF/Cu groups showed greater loss of body weight than the sorafenib + DSF group (6.76% and 16.52% loss, p=0.034 and 0.0057, respectively) (Figure 6E). No DSF-associated drug toxicity was observed in this in vivo model. On the contrary, DSF showed evidence of protection against sorafenib treatment-induced weight loss.

**DISCUSSION**

Considerable evidence indicates that HCSCs sustain tumor growth, produce differentiated progeny, and eventually result in tumor metastasis (32, 33). In addition to scientific consensus on their role in cancer is the finding that the presence of HCSCs is associated with poor prognosis and is predictive of clinical outcomes (34). Therefore, in this study, we aimed to develop an effective approach to targeting HCSCs to improve the efficacy of current chemotherapy for patients with advanced HCC.

The chemoresistance of HCSCs also extends to sorafenib (16). We found that sorafenib had a limited effect on HCSCs identified as ALDH⁺ HCC cells by flow cytometry or through their sphere formation ability. This could explain why many patients with advanced HCC are not sensitive to sorafenib. Increasing evidence from preclinical studies indicates that combining sorafenib with other drugs can enhance its anti-tumor efficacy (35, 36). However, poor clinical efficacy and undesirable side effects limit the clinical application of combined drug therapy in patients with advanced HCC (37, 38). Therefore, any successful method for improving cell sensitivity and reversing resistance to sorafenib has clinical potential.

DSF is an ALDH inhibitor that is shown to exert anti-tumor activity in multiple mouse syngeneic and xenograft tumor models and cancer patients (18, 27, 39–41). We previously demonstrated that DSF/Cu targets CSCs and thereby improves the efficacy of standard chemotherapy or radiotherapy in pancreatic ductal adenocarcinoma, breast cancer and chondrosarcoma (18, 27, 28, 41). The same conclusion was obtained in the present study using HCC cell lines by detecting the proportion of ALDH⁺ cells to identify HCSCs and assessing their sphere formation ability and expression of stemness genes HER2, SOX9, and c-Myc. Whereas exogenously supplied Cu²⁺ is needed for DSF to target CSCs and induce cancer cell apoptosis in vitro (18), exogenously supplied Cu²⁺ is not required in vivo. The liver plays an important role in the supply, storage, and secretion of Cu²⁺ (42). Compared with patients with benign liver diseases, HCC patients show much higher levels of serum Cu²⁺ (43), which are strongly associated with poor HCC-specific survival (44). In addition, compared with normal liver tissues or a primary hepatocyte line, HCC tissue or HCC tissues or HCC cell lines exhibit excessive accumulation of Cu²⁺ (45, 46). These facts may explain why the supplied exogenous Cu²⁺ reduced the anti-tumor effect of DSF accompanied by weight loss in the HCC mouse model used in this study, as Cu²⁺ at a higher dose, e.g., 5 µM is tumor-promoting (47) and Cu²⁺ is necessary for toxicity of DSF at concentrations < 4 µM (48). Relevantly, the high level of Cu²⁺ in liver may explain the failure of DSF and exogenous Cu²⁺ in a previous clinical trial for treatment of refractory solid tumors metastasized to liver (NCT00742911), suggesting that Cu²⁺ levels in tumor tissues and/or serum should be taken into consideration when conducting future clinical trials involving DSF.

The present study aimed to improve the efficacy of sorafenib for treating advanced HCC by repurposing DSF targeting HCSCs. As expected, DSF/Cu and sorafenib synergistically inhibited the growth of HCC cells in vitro. Compared with either drug used as monotherapy, the combination of DSF/Cu and sorafenib was more effective in eliminating HCSCs and induced more potent autophagy and apoptosis. The anti-tumor activity of sorafenib was attributed to its inhibition of angiogenesis (VEGFR and PDGFR) and direct effect on tumor cell proliferation and survival (RAF/MEK/ERK pathway) (23). Previous studies demonstrate that an MEK inhibitor combined with sorafenib synergistically exhibits anti-tumor activity (49, 50). In addition, some studies show that MEK inhibition can reduce the proliferation and self-renewal of CSCs in many tumor types, including HCC (51–53). Therefore, we suspected that DSF/Cu could serve as a MEK inhibitor to improve the anti-tumor effect of sorafenib. Surprisingly, however, DSF/Cu was found to activate the ERK/
MEK signaling pathway and sustain high expression of p-ERK and p-MEK, which was associated with the loss of stemness gene expression. This finding is contrary to those of previous studies, which suggest that MEK inhibition contributes to the apoptosis of HCC cells and HCSGs (23, 51). Furthermore, substantial evidence indicates that high expression of p-ERK may serve as a good prognostic biomarker for sorafenib response in HCC (54, 55). The synergistic effect of DSF/Cu + sorafenib on HCC can be interpreted by the fact that DSF/Cu maintains activation of ERK/MER pathway, which is harmful to HCC cells and HCSGs, and elevates p-ERK, thereby improving the sensitivity of HCC to sorafenib. It is important to further study the mechanisms of DSF/Cu + sorafenib on bulk HCC cells and sorted HCSGs. Also, we plan to establish sorafenib-resistant HCC cell lines to further reveal the mechanisms involved.

To generate more clinically relevant and translational data on DSF/Cu + sorafenib therapy, we established an orthotopic HCC xenograft model in mice and found that combination therapy was significantly more effective in inhibiting xenografts than monotherapy. Of note, DSF did not cause additional toxicity but appeared to have a protective role, consistent with our previous results in pancreatic ductal adenocarcinoma and breast cancer mouse models (18, 27). Together, these in vitro and in vivo findings provide a foundation for further developing an effective clinical strategy involving the repurposing of DSF to enhance the therapeutic efficacy of sorafenib against HCC.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492
2. Ferlay J, Colombe M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the Global Cancer Incidence and Mortality in 2018: Globocan Sources and Methods. Int J Cancer (2019) 144(8):1941–53. doi: 10.1002/ijc.31937
3. Erstad DJ, Tanabe KK. Hepatocellular Carcinoma: Early-Stage Management Challenges. J Hepatobiliary Pancreat Sci (2017) 4:1–2. doi: 10.2147/JHPBS.S70730
4. Lei C, Ren D, Fu M, Sun C, Ren H, Pan Q, et al. Curative Effect of Endostar and Its Inhibitory Effect on HCC Cell Lines via Activation-Related Genes. Oncol Lett (2017) 13(4):3665–70. doi: 10.3892/ol.2017.9022
5. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and Development of Sorafenib: A Multikinase Inhibitor for Treating Cancer. Nat Rev Drug Discovery (2006) 5(10):835–44. doi: 10.1038/nrd2130
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region With Advanced Hepatocellular Carcinoma: A Phase II Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Oncol (2009) 10(1):25–34. doi: 10.1016/S1470-2045(08)70285-7
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med (2008) 359(4):378–90. doi: 10.1056/NEJMoa0708857
8. Liang Y, Zhang J, Zhang X, Zhou H, Liu G, Li Q. Cancer Stem Cells: A Potential Breakthrough in HCC-Targeted Therapy. Adv Med Oncol (2015) 2015-309501
9. Wang N, Wang S, Li MY, Hu BG, Liu LP, Yang SL, et al. Cancer Stem Cells in Hepatocellular Carcinoma: An Overview and Promising Therapeutic Strategies. Ther Adv Med Oncol (2018) 10:175883918816287. doi: 10.1177/175883918816287
10. Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, et al. Tumour Suppresser-Dependent Hif-1alpha Inhibition in Hepatocellular Carcinoma. Hepatology (2015) 57(3):1847–57. doi: 10.1002/hep.26224
11. Wang N, Wang S, Li MY, Hu BG, Li P, Yang SL, et al. Cancer Stem Cells in Hepatocellular Carcinoma: An Overview and Promising Therapeutic Strategies. Ther Adv Med Oncol (2018) 10:175883918816287. doi: 10.1177/175883918816287
12. Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, et al. Tumour Initiating Cells and IGF/EGF Signalling Contribute to Sorafenib Resistance in Hepatocellular Carcinoma. Gut (2017) 66(3):530–40. doi: 10.1136/gutjnl-2015-309501
13. Wu Y, Zhang J, Zhang X, Zhou H, Liu G, Li Q. Cancer Stem Cells: A Potential Breakthrough in HCC-Targeted Therapy. Front Pharmacol (2020) 11:198. doi: 10.3389/fphar.2020.00198
14. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, et al. Aldehyde Dehydrogenase Discriminates the Cd133 Liver Cancer Stem Cell Populations. Mol Cancer Res (2008) 6(7):1146–53. doi: 10.1158/1541-7786.MCR-08-0035

ETHICS STATEMENT

The animal study was reviewed and approved by The Institutional Animal Care and Use at the Massachusetts General Hospital.

AUTHOR CONTRIBUTIONS

XW conceived and designed this study. GZ, YW, WG, LC, DE, and LZ collected the data. GZ, YW, XW, BF, DE, HZ, and KT analysed and interpreted the data. YW, XW, AD and DD were involved in writing, revision of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants R01CA226981(XW) and W81XWH-20-PCRP-IDA (W81XWH2110433, XW).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.913736/full#supplementary-material

Supplementary Figure 1 | DSF/Cu downregulates the expression of stemness gene encode proteins and induces autophagic cell death via sustained activation of the ERK signaling pathway. The HCC cell lines HepG2, Hep3B, SNU387, and SNU423 were treated with DSF/Cu (0.4µM/1µM). Treated cells were lysed at different time points and analyzed by western blot for the expression of stemness genes encoded proteins, autophagy, apoptosis markers, and MEK/ERK pathway activation-related genes. The band density of each protein was quantified with ImageJ. The mean ± SD of each protein from 2 independent blots (while the protein expression level was relative to 0 h time point) are shown. * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and **** indicates p<0.0001.
13. Moreb JS, Aldehyde Dehydrogenase as a Marker for Stem Cells. Curr Stem Cell Res Ther (2008) 3(4):237–46. doi: 10.2174/157488808786730406
14. Nito K, Yamashita T, Kanazawa S. The Evolving Concept of Liver Cancer Stem Cells. Mol Cancer (2017) 16(1):4. doi: 10.1186/s12943-016-0572-9
15. Chow AK, Ng L, Lam CS, Wong SK, Wan TM, Cheng NS, et al. The Enhanced Metastatic Potential of Hepatocellular Carcinoma (Hcc) Cells With Sorafenib Resistance. PLoS One (2013) 8(11):e78675. doi: 10.1371/journal.pone.0078675
16. Xin HW, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen JQ, et al. Recognition of Her2 Cancer Stem Cells in Hepatocellular Carcinoma and Its Significance in Hepatocellular Carcinoma. Proc Natl Acad Sci U S A (2016) 113(25):7077–82. doi: 10.1073/pnas.1607197113
17. Li H, Wang J, Cheng JC, Thakur A, Yi Y, Tsai SH, Hoodless PA, et al. YAP Heterogeneity in HCC Stem Cells. J Cell Biol (2017) 216(10):3611–22. doi: 10.1083/jcb.201708028
18. Li C, Liu C, Chen X, Cheng J, Zhang H, Shen J, et al. Sox9 Regulates Self-Renewal and Tumorigenicity by Promoting Symmetrical Cell Division of Cancer Stem Cells in Hepatocellular Carcinoma. Hepatology (2016) 64(1):117–29. doi: 10.1002/hep.28509
19. Shi JH, Guo WZ, Jin Y, Zhang HP, Pang C, Li J, et al. Recognition of Her2 Expression in Hepatocellular Carcinoma and Its Significance in Postoperative Tumor Recurrence. Cancer Med (2019) 8(3):2697–704. doi: 10.1002/cam4.2004
20. Cong J, Wang Y, Zhang X, Zhang N, Liu S, Soukup K, et al. A Novel Chemoradiation Targeting Stem and Nonstem Pancreatic Cancer Cells by Repurposing Disulfiram. Cancer Lett (2017) 409:9–19. doi: 10.1016/j.canlet.2017.08.004
21. Liu C, Liu C, Chen X, Engel J, Zhang H, Shen J, et al. Sox9 Regulates Self-Renewal and Tumorigenicity by Promoting Symmetrical Cell Division of Cancer Stem Cells in Hepatocellular Carcinoma. Hepatology (2016) 64(1):117–29. doi: 10.1002/hep.28509
22. Elbadawy M, Usui T, Yamawaki H, Sasaki K. Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer. Int J Mol Sci (2019) 20(9):2340. doi: 10.3390/ijms20092340
23. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib Blocks the Raf/Mek/Erk Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model Plc/Prf/5. J Cell Mol Med (2018) 22(11):4391–41. doi: 10.1111/jcmm.13343
24. Wang Y, Li W, Patel SS, Cong J, Zhang N, Sabbatinio F, et al. Blocking the Formation of Radiation-Induced Breast Cancer Stem Cells. Oncotarget (2014) 5(11):3743–55. doi: 10.18632/oncotarget.1992
25. Wang Y, Sun T, Yang W, To PM, Tsoi E, DeLeo AB, et al. Induction of Immunogenic Cell Death in Radiation-Resistant Breast Cancer Stem Cells by Repurposing Anti-Alcoholism Drug Disulfiram. Cell Commun Signal (2020) 18(1):36. doi: 10.1186/s12943-019-0507-3
26. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular Mechanisms of Cell Death: Recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ (2018) 25(3):486–541. doi: 10.1038/s41418-017-0012-4
27. Yang S, Liu G. Targeting the Ras/Raf/Mek/Erk Pathway in Hepatocellular Carcinoma. Oncol Lett (2017) 13(3):1041–7. doi: 10.3892/ol.2017.5557
28. Vecchio FM, Federico F, Dina MA. Copper and Hepatocellular Carcinoma. Digestion (1986) 35(2):109–14. doi: 10.1159/000199354
29. Karakasiliotis I, Mamvromma P. Hepatocellular Carcinoma: From Hepatocyte to Liver Cancer Stem Cell. Front Physiol (2015) 6:154. doi: 10.3389/ fpsyt.2015.00154
30. Lee JS, Heo J, Llibrechech L, Chu IS, Kaposis-Novak P, Calvisi DF, et al. A Novel Prognostic Subtype of Human Hepatocellular Carcinoma Derived From Hepatic Progenitor Cells. Nat Med (2006) 12(4):410–6. doi: 10.1038/nm1377
31. Zhang X, Hu P, Ding SY, Sun T, Liu L, Panera N, Crudele A, et al. Focal Adhesion Kinase Inhibitor Tae226 Combined With Sorafenib Slows Down Hepatocellular Carcinoma by Multiple Epigenetic Effects. J Exp Clin Cancer Res (2021) 40(1):364. doi: 10.1186/s13046-021-02154-8
32. Mokdad AA, Zhu H, Beg MS, Arriaga Y, Dowell JE, Singal AG, et al. Efficacy and Safety of Bavituximab in Combination With Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. J Clin Oncol (2019) 37(15):541–50. doi: 10.1200/jco.2019.315219-00663-3
33. Riano J, Martin L, Varela M, Serrano T, Nunez O, Miguez B, et al. Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (Estaehep Clinical Trial). Cancers (Basel) (2020) 12(7):1900. doi: 10.3390/cancers12071900
34. Fang AP, Cheng JC, Yi Y, Tsai SH, Hoodless PA. YAP Overcomes Sorafenib Resistance in Hepatocellular Carcinoma. Int J Cancer (2017) 141(12):2571–84. doi: 10.1002/ijc.31022
35. Zhang X, Hu P, Ding SY, Sun T, Liu L, Han S, et al. Induction of Autophagy-Dependent Apoptosis in Cancer Cells Through Activation of Er Stress: An Uncovered Anti-Cancer Mechanism by Anti-Alcoholism Drug Disulfiram. Am J Cancer Res (2019) 9(6):1266–81. doi: 10.22032/ajcr.09.06.1266
36. Li C, Liu C, Chen X, Cheng J, Zhang H, Shen J, et al. Sox9 Regulates Self-Renewal and Tumorigenicity by Promoting Symmetrical Cell Division of Cancer Stem Cells in Hepatocellular Carcinoma. Hepatology (2016) 64(1):117–29. doi: 10.1002/hep.28509
37. Haratake J, Horie A, Takeda S, Kobori K, Sato H, Tokudome S. Tissue Copper Content in Primary and Metastatic Liver Cancers. J Nucl Med (2013) 54(6):953–60. doi: 10.2967/jnumed.112.113324
38. Schneider R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, et al. Allosteric Mek1/2 Inhibitor Refametinib (Bay 86-7661) in Combination With Sorafenib Exhibits Antitumor Activity in Predilucine Murine and Rat Models of Hepatocellular Carcinoma. Neoplasia (2013) 15(10):1161–7. doi: 10.1593/neo.130812
39. Porcu C, Antonucci L, Barbaro B, Illi B, Nasi S, Martini M, et al. Copper/Myc/ Ctrl Interplay: A Dangerous Relationship in Hepatocellular Carcinoma. Oncotarget (2018) 9(10):9325–43. doi: 10.18632/oncotarget.24282
40. Rae C, Tesson M, Babich JW, Boyd M, Sorenson A, Mairs RJ. The Role of Copper in Disulfiram-Induced Toxicity and Radiosensitization of Cancer Cells. J Nucl Med (2013) 54(6):953–60. doi: 10.2967/jnumed.112.113324
41. Cheng J, Liu C, Liu C, Chen X, Shan J, Shen J, et al. Mek1 Signaling Promotes Self-Renewal and Tumorigenicity of Liver Cancer Stem Cells Via Maintaining
Sirt1 Protein Stabilization. Oncotarget (2016) 7(15):20597–611. doi: 10.18632/oncotarget.7972
52. Ciccarelli C, Vulcano F, Milazzo L, Gravina GL, Marampon F, Macioce G, et al. Key Role of Mek/Erk Pathway in Sustaining Tumorigenicity and In Vitro Radioresistance of Embryonal Rhabdomyosarcoma Stem-Like Cell Population. Mol Cancer (2016) 15:16. doi: 10.1186/s12943-016-0501-y
53. Walter K, Tiwary K, Trajkovic-Arsic M, Hidalgo-Sastre A, Dierichs L, Liffers ST, et al. Mek Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo. Stem Cells Int (2019) 2019:8475389. doi: 10.1155/2019/8475389
54. Wang C, Jin H, Gao D, Lieftink C, Evers B, Jin G, et al. Phospho-Erk Is a Biomarker of Response to a Synthetic Lethal Drug Combination of Sorafenib and Mek Inhibition in Liver Cancer. J Hepatol (2018) 69(5):1057–65. doi: 10.1016/j.jhep.2018.07.004
55. Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated Erk Is a Potential Predictor of Sensitivity to Sorafenib When Treating Hepatocellular Carcinoma: Evidence From an In Vitro Study. BMC Med (2009) 7:41. doi: 10.1186/1741-7015-7-41

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Wang, Fucho, Guo, Drum, Erstad, Shi, DeLeo, Zheng, Cai, Zhang, Tanabe and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.